[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"platelet-aggregation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:platelet-aggregation":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,51,84,110],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100642949","a-single-center-randomized-double-blind-placebo-controlled-intervention-clinical-trial-to-evaluate-the-efficacy-and-safety-of-koreaginseng-f-max-on-blood-circulation-improvement-in-adults-with-poor-peripheral-blood-flow-100642949",false,"NCT07643532","A Single-center, Randomized, Double-blind, Placebo-controlled, Intervention Clinical Trial to Evaluate the Efficacy and Safety of \"KoreaGinseng F Max\" on Blood Circulation Improvement in Adults With Poor Peripheral Blood Flow","Inclusion Criteria:\n\n* Men or women aged 20 to under 65 years\n* Platelet aggregation response above 55% (satisfied for both collagen and ADP)\n* Provides voluntary written informed consent to participate\n\nExclusion Criteria:\n\n* History of hypersensitivity or allergy to ginseng-containing products that may affect the results\n* Surgery under general anesthesia within 12 weeks before participation\n* Use of contraindicated products such as red ginseng or omega-3 fatty acids within 2 weeks before screening\n* Use of antiplatelet drugs such as aspirin within 2 weeks before screening (subjects on prophylactic aspirin \\\u003C100 mg with unchanged dose\u002Fmethod may participate)\n* Uncontrolled hypertension not managed by medication (systolic BP \\>160 mmHg or diastolic BP \\>97 mmHg)\n* Currently using study-indicated medications such as those for dyslipidemia or diabetes\n* On drug treatment with a history of peripheral atherosclerosis and coronary artery disease (peripheral vascular disease, abdominal aortic aneurysm, carotid artery disease)\n* Coronary artery bypass surgery, vascular anastomosis, pacemaker use, myocardial infarction, heart failure, arrhythmia, or other cardiac disease within 6 months\n* Infectious inflammatory disease, systemic infection, immune-resistance-related disease, or leukemia (blood cancer)\n* Irritable bowel syndrome, gastrointestinal resection surgery, or GI-related disease such as Crohn's disease\n* History of cerebral ischemia or cerebral hemorrhage such as cerebral infarction or stroke due to atherosclerosis\n* Concurrent symptoms of myocardial infarction, atherosclerosis, or congestive heart failure\n* Clinically significant liver dysfunction (ALT or AST ≥2.5x the upper limit of normal)\n* Clinically significant renal dysfunction (serum creatinine \\>2.0 mg\u002FdL)\n* TSH outside 0.27-5.07 microIU\u002FmL or thyroid disease\n* History of, or current treatment for, psychiatric\u002Fneurological disorders including schizophrenia, depression, or drug addiction\n* History of malignant tumor within 5 years before screening\n* Pregnant or breastfeeding women, women of childbearing potential not using medically reliable contraception, or women within 6 months postpartum\n* Alcohol consumption within the last 3 days (men 30 g\u002Fday, women 20 g\u002Fday)\n* Participation in another clinical trial within 4 weeks before participation\n* Subjects judged unsuitable by the investigator or other physicians",true,"ALL","20 Years","65 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a single-center, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of a white ginseng extract (KoreaGinseng F Max) for improving blood circulation in adults with poor peripheral blood flow.\n\nA total of 100 adults aged 20 to under 65 years with platelet aggregation above 55% will be enrolled and randomly assigned in a 1:1 ratio to receive either the white ginseng extract or a matching placebo for 8 weeks. Each participant takes 3 tablets after breakfast and 3 tablets after dinner (6 tablets per day).\n\nThe main goal is to measure the change in ADP-induced platelet aggregation from baseline (Visit 2) to the end of treatment (Visit 4, Week 8). The study also assesses effects on coagulation measures, blood lipids, serotonin, blood pressure, white blood cell count, and overall safety.",[27,28,29],"Blood Circulation","Peripheral Blood Flow","Platelet Aggregation",[31,32,33,34,35,36,37],"White ginseng extract","KoreaGinseng F Max","Platelet aggregation","Blood circulation","Antiplatelet","Dietary supplement","Functional food","NOT_YET_RECRUITING","2026-06-08",{"date":41,"type":42},"2026-06-11","ACTUAL",{"date":44,"type":21},"2026-06-10",{"date":46,"type":21},"2028-06-10",{"name":48,"class":49},"Haiphong University of Medicine and Pharmacy","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":63,"conditions":64,"keywords":69,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":50},"100493231","phase-1-assessing-pharmacokinetics-and-pharmacodynamics-of-daily-enteric-coated-aspirin-in-patients-with-stable-diabetes-ii-100493231","NCT05702463","Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes II","APPEASEDII","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Participant must be naïve to ASA, defined as absence of chronic treatment with ASA within the previous 3 months, and of any ASA use within the previous 2 weeks;\n3. Type 2 diabetes, based on at least one of the following criteria: (5)\n\n   * Chronic treatment with oral antihyperglycemic agents or insulin therapy;\n   * Fasting Plasma Glucose (FPG) ≥ 126 mg\u002FdL (7.0 mmol\u002FL) (fasting is defined as no caloric intake for at least 8h);\n   * 2-h Plasma Glucose (2h-PG) ≥ 200 mg\u002FdL (11.1 mmol\u002FL) during the oral glucose tolerance test (OGTT);\n   * A1C ≥ 6.5% (48 mmol\u002Fml);\n4. Willing to attend all study visits of both the run-in and randomized phases of the trial.\n\nExclusion Criteria:\n\n1. Definitive indication for ASA, including any evidence of clinical atherosclerotic disease, previous or current;\n2. Known hypersensitivity to ASA;\n3. Patient requiring dialysis;\n4. Severe hepatic insufficiency or ALT \\> 3 x ULN;\n5. High-risk GI bleeding features, such as known H. pylori infection, past or present ulcer, history of bleeding from the GI tract;\n6. Bleeding diathesis;\n7. Platelet count or hemoglobin levels outside of the normal reference range;\n8. Planned major surgical procedure or dental procedure during the course of the study;\n9. Chronic inflammatory disease requiring regular anti-inflammatory treatment;\n10. Chronic treatment with an oral anticoagulant, an antiplatelet agent, NSAIDs or systemic steroids;\n11. Active cancer;\n12. History of hematological malignancy or myelodysplasia;\n13. Pregnant or lactating women;","18 Years",{"count":60,"type":21},30,[62],"PHASE1","This phase 2 study will include patients suffering from type 2 diabetes mellitus and will first study their response to enteric coated aspirin at a dose of 80 mg per day for a 7-day period. Participants with an incomplete platelet inhibition after exposure to EC aspirin at doses of 80 mg once daily will be randomized to a random order of 3 different ASA regimens: EC ASA 162 mg once daily, EC ASA 81 mg twice daily and chewable ASA 40 mg twice daily. The aims are to determine the feasibility of a larger scale trial, and to determine the regimen associated with the lowest proportion of non-responders after randomization. Platelet function will be assessed at baseline and at day 7 of each arms of the study.",[29,65,66,67,68],"Type 2 Diabetes","Aspirin","Diabetes Mellitus, Type 2","Platelet Aggregation Inhibitors",[70,71,72,73],"diabetes","aspirin","Acetylsalicylic acid","Pharmacodynamics","RECRUITING","2025-12-02",{"date":77,"type":42},"2025-12-03",{"date":79,"type":42},"2023-06-13",{"date":81,"type":21},"2027-07-01",{"name":83,"class":49},"Montreal Heart Institute",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":58,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":50},"100614126","platelet-aggregation-in-the-diagnosis-of-acute-graft-rejection-100614126","NCT07275541","Platelet Aggregation in the Diagnosis of Acute Graft Rejection","Inclusion Criteria:\n\n* adult patients (≥18 years)\n* primary kidney transplantation\n* living \u002F deceased donor kidney transplantation\n* ability and consent to participate\n\nExclusion Criteria:\n\n* non-adult patients\n* secondary \u002F tertiary kidney transplantation\n* antiplatelet therapy\n* patients unable to provide informed consent",{"count":91,"type":21},60,"OBSERVATIONAL","The study titled \"Platelet Aggregation in the Diagnosis of Acute Graft Rejection\" is a pilot observational study evaluating whether alterations in platelet function can serve as non-invasive markers of acute rejection in kidney transplant recipients. Platelet aggregation is assessed using optical aggregometry, flow-cytometric P-selectin (CD62-P) expression, and soluble P-selectin levels before kidney transplantation and at the time of protocol biopsies performed at 3 and 12 months after kidney transplantation. Patients with suspected graft dysfunction undergoing indication biopsy are also included. Platelet activation markers are correlated with histopathological findings, donor-specific antibodies, metabolic parameters, and clinical outcomes. The goal is to determine whether platelet activation profiles can identify acute cellular or antibody-mediated rejection and contribute to the development of a non-invasive diagnostic tool.",[29,95],"Kidney Transplant Rejection",[97,98,99,100],"kidney transplantation","platelet aggregation","acute rejection","non-invasive marker","2025-11-27",{"date":103,"type":42},"2025-12-10",{"date":105,"type":42},"2024-11-26",{"date":107,"type":21},"2027-11-26",{"name":109,"class":49},"University Hospital, Martin",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":16,"minAge":58,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":121,"briefSummary":123,"conditions":124,"keywords":136,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":50},"100608614","phase-4-modulation-of-gut-microflora-with-rifaximin-to-reduce-high-platelet-reactivity-in-post-acs-patients-on-ticagrelor-100608614","NCT07203846","Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor","Modulation of Gut Microflora With Rifaximin to Reduce High Platelet Reactivity in Post-Acute Coronary Syndrome Patients on Ticagrelor (FLORA-ACS)","FLORA-ACS","Inclusion criteria:\n\n* Between 18 and 80 years of age\n* History of acute coronary syndrome no sooner than 1 month and no later than 12 months prior to study inclusion\n* Current treatment with ticagrelor (90 mg orally twice a day)\n* High platelet reactivity assessed with multiple electrode aggregometry method (AUC of \\>46 U)\n* Provision of informed consent prior to any study procedures\n\nExclusion criteria:\n\n* History of hypersensitivity to rifaximin or other rifamycin-derived agent\n* Ongoing treatment with rifamycins\n* Platelet count \\\u003C 100×10\\^9\u002FL or \\> 450×10\\^9\u002FL\n* Treatment with antibiotics, probiotics, or glucocorticoids within 3 months prior to study inclusion\n* History of gastrointestinal diseases such as inflammatory bowel disease, bowel obstruction, or gastrointestinal tumor\n* Infection, including gastrointestinal infection, within a month prior to study inclusion\n* History of Clostridium difficile infection\n* Current use of specific medications (warfarin, glycoprotein IIb\u002FIIIa inhibitors, immunosuppressants, bile acid sequestrants, antidiarrheal agents)\n* Impaired liver function classified as Child-Pugh class B or C\n* Hemodynamic instability\n* Pregnancy or breastfeeding\n* Patients considered by the investigator to be uncooperative","80 Years",{"count":120,"type":21},50,[122],"PHASE4","The FLORA-ACS study aims to evaluate the relationship between dysbiosis and high platelet reactivity during treatment with ticagrelor in patients with a history of acute coronary syndromes and investigate the use of rifaximin to eliminate dysbiosis and thus provide effective antiplatelet treatment.",[125,126,127,29,128,129,130,68,131,132,133,134,135],"ACS - Acute Coronary Syndrome","Ticagrelor","Microbiota","Myocardial Infarction (MI)","Blood Platelets","Drug Effects","Drug Resistance","Platelet Function Tests","Dysbiosis","Anti-Bacterial Agents","Rifaximin",[137,138,139,140,141,142,143,144,145,146],"high platelet reactivity","HPR","Multiplate aggregometry","multiple electrode aggregometry","MEA","microbiome","gut flora","eubiotic","16S rRNA sequencing","P2Y12 inhibitor","2025-09-25",{"date":149,"type":42},"2025-10-02",{"date":151,"type":21},"2026-01-01",{"date":153,"type":21},"2027-06-30",{"name":155,"class":49},"Collegium Medicum w Bydgoszczy"]